Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies

Fig. 2

Targeting ability of the drug-loaded immunolipoplex. a The effect of antibody association with immunocomplexes on cell targeting in vitro. The HER2/neu receptor expressed on different cancer cell lines were indirectly probed with the humanized antibodies, Herceptin or Rituximab, and FITC-conjugated goat anti-human IgG antibody. Herceptin or Rituximab were adsorbed on DiO-labeling LPPC to monitor their ability to target breast cancer cell lines when associated with LPPC complexes. b The intracellular accumulation of curcumin. MCF-7 cells were treated with curcumin, curcumin/LPPC/Rituximab or curcumin/LPPC/Herceptin at equal concentrations of curcumin. The cell membranes were stained with red fluorescent dye DiI, the nuclei were stained with DAPI, and the cellular distribution of curcumin is shown as green fluorescence signal. The cells were imaged using a confocal microscope. c Targeting ability of LPPC in vivo. DiI-labeled LPPC/Rituximab or DiI-labeled LPPC/Herceptin complexes were i.v. injected into athymic nude mice bearing HER2-negative Hs578T cell and HER2-positive SKBR3 cell-induced tumors. The images were obtained by IVIS at 0, 24, 48 and 72 h after injection. The photon counts of each mouse are indicated by the pseudo-color scales. d After 72 h, the organs and tumors isolated from the treated nude mice were imaged by IVIS

Back to article page